Going to extremes

determinants of extraordinary response and survival in patients with cancer

Flurina A.M. Saner, Alan Herschtal, Brad H. Nelson, Anna deFazio, Ellen L Goode, Susan J. Ramus, Ahwan Pandey, Jessica A. Beach, Sian Fereday, Andrew Berchuck, Stephanie Lheureux, Celeste Leigh Pearce, Paul D. Pharoah, Malcolm C. Pike, Dale W. Garsed, David D.L. Bowtell

Research output: Contribution to journalReview article

Abstract

Research into factors affecting treatment response or survival in patients with cancer frequently involves cohorts that span the most common range of clinical outcomes, as such patients are most readily available for study. However, attention has turned to highly unusual patients who have exceptionally favourable or atypically poor responses to treatment and/or overall survival, with the expectation that patients at the extremes may provide insights that could ultimately improve the outcome of individuals with more typical disease trajectories. While clinicians can often recount surprising patients whose clinical journey was very unusual, given known clinical characteristics and prognostic indicators, there is a lack of consensus among researchers on how best to define exceptional patients, and little has been proposed for the optimal design of studies to identify factors that dictate unusual outcome. In this Opinion article, we review different approaches to identifying exceptional patients with cancer and possible study designs to investigate extraordinary clinical outcomes. We discuss pitfalls with finding these rare patients, including challenges associated with accrual of patients across different treatment centres and time periods. We describe recent molecular and immunological factors that have been identified as contributing to unusual patient outcome and make recommendations for future studies on these intriguing patients.

Original languageEnglish (US)
JournalNature Reviews Cancer
DOIs
StatePublished - Jan 1 2019

Fingerprint

Survival
Neoplasms
Immunologic Factors
Therapeutics
Research Personnel
Research

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Going to extremes : determinants of extraordinary response and survival in patients with cancer. / Saner, Flurina A.M.; Herschtal, Alan; Nelson, Brad H.; deFazio, Anna; Goode, Ellen L; Ramus, Susan J.; Pandey, Ahwan; Beach, Jessica A.; Fereday, Sian; Berchuck, Andrew; Lheureux, Stephanie; Pearce, Celeste Leigh; Pharoah, Paul D.; Pike, Malcolm C.; Garsed, Dale W.; Bowtell, David D.L.

In: Nature Reviews Cancer, 01.01.2019.

Research output: Contribution to journalReview article

Saner, FAM, Herschtal, A, Nelson, BH, deFazio, A, Goode, EL, Ramus, SJ, Pandey, A, Beach, JA, Fereday, S, Berchuck, A, Lheureux, S, Pearce, CL, Pharoah, PD, Pike, MC, Garsed, DW & Bowtell, DDL 2019, 'Going to extremes: determinants of extraordinary response and survival in patients with cancer', Nature Reviews Cancer. https://doi.org/10.1038/s41568-019-0145-5
Saner, Flurina A.M. ; Herschtal, Alan ; Nelson, Brad H. ; deFazio, Anna ; Goode, Ellen L ; Ramus, Susan J. ; Pandey, Ahwan ; Beach, Jessica A. ; Fereday, Sian ; Berchuck, Andrew ; Lheureux, Stephanie ; Pearce, Celeste Leigh ; Pharoah, Paul D. ; Pike, Malcolm C. ; Garsed, Dale W. ; Bowtell, David D.L. / Going to extremes : determinants of extraordinary response and survival in patients with cancer. In: Nature Reviews Cancer. 2019.
@article{fa3bb120f8c4434aaf062979e862749f,
title = "Going to extremes: determinants of extraordinary response and survival in patients with cancer",
abstract = "Research into factors affecting treatment response or survival in patients with cancer frequently involves cohorts that span the most common range of clinical outcomes, as such patients are most readily available for study. However, attention has turned to highly unusual patients who have exceptionally favourable or atypically poor responses to treatment and/or overall survival, with the expectation that patients at the extremes may provide insights that could ultimately improve the outcome of individuals with more typical disease trajectories. While clinicians can often recount surprising patients whose clinical journey was very unusual, given known clinical characteristics and prognostic indicators, there is a lack of consensus among researchers on how best to define exceptional patients, and little has been proposed for the optimal design of studies to identify factors that dictate unusual outcome. In this Opinion article, we review different approaches to identifying exceptional patients with cancer and possible study designs to investigate extraordinary clinical outcomes. We discuss pitfalls with finding these rare patients, including challenges associated with accrual of patients across different treatment centres and time periods. We describe recent molecular and immunological factors that have been identified as contributing to unusual patient outcome and make recommendations for future studies on these intriguing patients.",
author = "Saner, {Flurina A.M.} and Alan Herschtal and Nelson, {Brad H.} and Anna deFazio and Goode, {Ellen L} and Ramus, {Susan J.} and Ahwan Pandey and Beach, {Jessica A.} and Sian Fereday and Andrew Berchuck and Stephanie Lheureux and Pearce, {Celeste Leigh} and Pharoah, {Paul D.} and Pike, {Malcolm C.} and Garsed, {Dale W.} and Bowtell, {David D.L.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41568-019-0145-5",
language = "English (US)",
journal = "Nature Reviews Cancer",
issn = "1474-175X",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Going to extremes

T2 - determinants of extraordinary response and survival in patients with cancer

AU - Saner, Flurina A.M.

AU - Herschtal, Alan

AU - Nelson, Brad H.

AU - deFazio, Anna

AU - Goode, Ellen L

AU - Ramus, Susan J.

AU - Pandey, Ahwan

AU - Beach, Jessica A.

AU - Fereday, Sian

AU - Berchuck, Andrew

AU - Lheureux, Stephanie

AU - Pearce, Celeste Leigh

AU - Pharoah, Paul D.

AU - Pike, Malcolm C.

AU - Garsed, Dale W.

AU - Bowtell, David D.L.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Research into factors affecting treatment response or survival in patients with cancer frequently involves cohorts that span the most common range of clinical outcomes, as such patients are most readily available for study. However, attention has turned to highly unusual patients who have exceptionally favourable or atypically poor responses to treatment and/or overall survival, with the expectation that patients at the extremes may provide insights that could ultimately improve the outcome of individuals with more typical disease trajectories. While clinicians can often recount surprising patients whose clinical journey was very unusual, given known clinical characteristics and prognostic indicators, there is a lack of consensus among researchers on how best to define exceptional patients, and little has been proposed for the optimal design of studies to identify factors that dictate unusual outcome. In this Opinion article, we review different approaches to identifying exceptional patients with cancer and possible study designs to investigate extraordinary clinical outcomes. We discuss pitfalls with finding these rare patients, including challenges associated with accrual of patients across different treatment centres and time periods. We describe recent molecular and immunological factors that have been identified as contributing to unusual patient outcome and make recommendations for future studies on these intriguing patients.

AB - Research into factors affecting treatment response or survival in patients with cancer frequently involves cohorts that span the most common range of clinical outcomes, as such patients are most readily available for study. However, attention has turned to highly unusual patients who have exceptionally favourable or atypically poor responses to treatment and/or overall survival, with the expectation that patients at the extremes may provide insights that could ultimately improve the outcome of individuals with more typical disease trajectories. While clinicians can often recount surprising patients whose clinical journey was very unusual, given known clinical characteristics and prognostic indicators, there is a lack of consensus among researchers on how best to define exceptional patients, and little has been proposed for the optimal design of studies to identify factors that dictate unusual outcome. In this Opinion article, we review different approaches to identifying exceptional patients with cancer and possible study designs to investigate extraordinary clinical outcomes. We discuss pitfalls with finding these rare patients, including challenges associated with accrual of patients across different treatment centres and time periods. We describe recent molecular and immunological factors that have been identified as contributing to unusual patient outcome and make recommendations for future studies on these intriguing patients.

UR - http://www.scopus.com/inward/record.url?scp=85065762409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065762409&partnerID=8YFLogxK

U2 - 10.1038/s41568-019-0145-5

DO - 10.1038/s41568-019-0145-5

M3 - Review article

JO - Nature Reviews Cancer

JF - Nature Reviews Cancer

SN - 1474-175X

ER -